FIG. 1A

1	CCTACTCTAT	TCAGATATTC	TCAGATATTC	TCAGATATTC	AGATCATTTC
51	TCATTCTCCT	AGGAGTACTC	ACTTCAGGAT	GCAACCAGAT	GTTTCGCAGT
101	TGCAACGGAA	GCCAGAACAT	TCCTCCTGGA	AATTCAACCT	GTTTCGCAGT
151	TTCTCGAGGA	ATCAGCATTC	AGTCAATCCG	GGCCGGGAGC	AGTCATCTGT
201	GGTGAGGCTG	ATTGGCTGGG	CAGGAACAGC	GCCGGGGCGT	GGGCTGAGCA
251	CAGCGCTTCG	CTCTCTTTGC	CACAGGAAGC	CTGAGCTCAT	TCGAGTAGCG
301	GCTCTTCCAA	GCTCAAAGAA	GCAGAGGCCG	CTGTTCGTTT	CCTTTAGGTC
351	TTTCCACTAA	AGTCGGAGTA	TCTTCTTCCA	AGATTTCACG	TCTTGGTGGC
401	CGTTCCAAGG	AGCGCGAGGT	CGGGATGGAT	CTTGAAGGGG	ACCGCAATGG
451	AGGAGCAAAG	AAGAAGAACT	TTTTTAAACT	GAACAATAAA	AGTGAAAAAG
501	ATAAGAAGGA	AAAGAAACCA	ACTGTCAGTG	TATTTTCAAT	GTTTCGCTAT
551	TCAAATTGGC	TTGACAAGTT	GTATATGGTG	GTGGGAACTT	TGGCTGCCAT

FIG. 1B

601	CATCCATGGG	GCTGGACTTC	CTCTCATGAT	GCTGGTGTTT	GGAGAAATGA
651	CAGATATCTT	TGCAAATGCA	GGAAATTTAG	AAAGATCTGAT	GTCAAACATC
701	ACTAATAGAA	GTGATATCAA	TGATACAGGG	TTCTTCATGA	ATCTGGAGGA
751	AGACATGACC	AGGTATGCCT	ATTATTACAG	TGGAATTGGT	GCTGGGGTGC
801	TGGTTGCTGC	TTACATTCAG	GTTTCATTTT	GGTGCCTGGC	AGCTGGAAGA
851	CAAATACACA	AAATTAGAAA	ACAGTTTTTT	CATGCTATAA	TGCGACAGGA
901	GATAGGCTGG	TTTGATGTGC	ACGATGTTGG	GGAGCTTAAC	ACCCGACTTA
951	CAGATGATGT	CTCCAAGATT	AATGAAGGAA	TTGGTGACAA	AATTGGAATG
1001	TTCTTTCAGT	CAATGGCAAC	ATTTTTCACT	GGGTTTATAG	TAGGATTTAC
1051	ACGTGGTTGG	AAGCTAACCC	TTGTGATTTT	GGCCATCAGT	CCTGTTCTTG
1101	GACTGTCAGC	TGCTGTCTGG	GCAAAGATAC	TATCTTCATT	TACTGATAAA
1151	GAACTCTTAG	CGTATGCAAA	AGCTGGAGCA	GTAGCTGAAG	AGGTCTTGGC

FIG. 1C

1201	AGCAATTAGA	ACTGTGATTG	CATTTGGAGG	ACAAAAGAAA	GAACTTGAAA
1251	GGTACAACAA	AAATTTAGAA	GAAGCTAAAA	GAATTGGGAT	AAAGAAAGCT
1351	TTATGCTCTG	GCCTTCTGGT	ATGGGACCAC	CTTGGTCCTC	TCAGGGGAAT
1401	ATTCTATTGG	ACAAGTACTC	ACTGTATTCT	TTTCTGTATT	AATTGGGGCT
1451	TTTAGTGTTG	GACAGGCATC	TCCAAGCATT	GAAGCATTTG	CAAATGCAAG
1501	AGGAGCAGCT	TATGAAATCT	TCAAGATAAT	TGATAATAAG	CCAAGTATTG
1551	ACAGCTATTC	GAAGAGTGGG	CACAAACCAG	ATAATATTAA	GGGAAATTTG
1601	GAATTCAGAA	ATGTTCACTT	CAGTTACCCA	TCTCGAAAAG	AAGTTAAGAT
1651	CTTGAAGGGC	CTGAACCTGA	AGGTGCAGAG	TGGGCAGACG	GTGGCCCTGG
1701	TTGGAAACAG	TGGCTGTGGG	AAGAGCACAA	CAGTCCAGCT	GATGCAGAGG
1751	CTCTATGACC	CCACAGAGGG	GATGGTCAGT	GTTGATGGAC	AGGATATTAG
1801	GACCATAAAT	GTAAGGTTTC	TACGGGAAAT	CATTGGTGTG	GTGAGTCAGG

FIG. 1D

1851	AACCTGTATT	GTTTGCCACC	ACGATAGCTG	AAAACATTCG	CTATGGCCGT
1901	GAAAATGTCA	CCATGGATGA	GATTGAGAAA	GCTGTCAAGG	AAGCCAATGC
1951	CTATGACTTT	ATCATGAAAC	TGCCTCATAA	ATTTGACACC	CTGGTTGGAG
2051	CGTGCCCTGG	TTCGCAACCC	CAAGATCCTC	CTGCTGGATG	AGGCCACGTC
2101	AGCCTTGGAC	ACAGAAAGCG	AAGCAGTGGT	TCAGGTGGCT	CTGGATAAGG
2151	CCAGAAAAGG	TCGGACCACC	ATTGTGATAG	CTCATCGTTT	GTCTACAGTT
2201	CGTAATGCTG	ACGTCATCGC	TGGTTTCGAT	GATGGAGTCA	TTGTGGAGAA
2251	AGGAAATCAT	GATGAACTCA	TGAAAGAGAA	AGGCATTTAC	TTCAAACTTG
2301	TCACAATGCA	GACAGCAGGA	AATGAAGTTG	AATTAGAAAA	TGCAGCTGAT
2351	GAATCCAAAA	GTGAAATTGA	TGCCTTGGAA	ATGTCTTCAA	ATGATTCAAG
2401	ATCCAGTCTA	ATAAGAAAAA	GATCAACTCG	TAGGAGTGTC	CGTGGATCAC
2451	AAGCCCAAGA	CAGAAAGCTT	AGTACCAAAG	AGGCTCTGGA	TGAAAGTATA

FIG. 1E

2501	CCTCCAGTTT	CCTTTTGGAG	GATTATGAAG	CTAAATTTAA	CTGAATGGCC
2551	TTATTTTGTT	GTTGGTGTAT	TTTGTGCCAT	TATAAATGGA	GGCCTGCAAC
2601	CAGCATTTGC	AATAATATTT	TCAAAGATTA	TAGGGGTTTT	TACAAGAATT
2651	GATGATCCTG	AAACAAAACG	ACAGAATAGT	AACTTGTTTT	CACTATTGTT
2701	TCTAGCCCTT	GGAATTATTT	CTTTTRTTAC	ATTTTTCCTT	CAGGGTTTCA
2751	CATTTGGCAA	AGCTCCAGAG	ATCCTCACCA	AGCGGCTCCG	ATACATGGTT
2801	TTCCGATCCA	TGCTCAGACA	GGATGTGAGT	TGGTTTGATG	ACCCTAAAAA
2851	CACCACTGGA	GCATTGACTA	CCAGGCTCGC	CAATGATGCT	GCTCAAGTTA
2901	AAGGGGCTAT	AGGTTCCAGG	CTTGCTGTAA	TTACCCAGAA	TATAGCAAAT
2951	CTTGGGACAG	GAATAATTAT	ATCCTTCATC	TATGGTTGGC	AACTAACACT
3001	GTTACTCTTA	GCAATTGTAC	CCATCATTGC	AATAGCAGGA	GTTGTTGAAA
3051	TGAAAATGTT	GTCTGGACAA	GCACTGAAAG	ATAAGAAAGA	ACTAGAAAAA

FIG. 1F

3101	GCTGGGAAGA	TCGCTACTGA	AGCAATAGAA	AACTTCCGAA	CCGTTGTTTC
3151	TTTGACTCAG	GAGCAGAAGT	TTGAACATAT	GTATGCTCAG	AGTTTGCAGG
3201	TACCATACAG	AAACTCTTTG	AGGAAAGCAC	ACATCTTTGG	AATTACATTT
3251	TCCTTCACCC	AGGCAATGAT	GTATTTTTCC	TATGCTGGAT	GTTTCCGGTT
3301	TGGAGCCTAC	TTGGTGGCAC	ATAAACTCAT	GAGCTTTGAG	GATGTTCTGT
3401	TCATTTGCTC	CTGACTATGC	CAAAGCCAAA	ATATCAGCAG	CCCACATCAT
3451	CATGATCATT	GAAAAAACCC	CTTTGATTGA	CAGCTACAGC	ACGGAAGGCC
3501	TAATGCCGAA	CACATTGGAA	GGAAATGTCA	CATTTGGTGA	AGTTGTATTC
3551	AACTATCCCA	CCCGACCGGA	CATCCCAGTG	CTTCAGGGAC	TGAGCCTGGA
3601	GGTGAAGAAG	GGCCAGACGC	TGGCTCTGGT	GGGCAGCAGT	GGCTGTGGGA
3651	AGAGCACAGT	GGTCCAGCTC	CTGGAGCGGT	TCTACGACCC	CTTGGCAGGG
3701	AAAGTGCTGC	TTGATGGCAA	AGAAATAAAG	CGACTGAATG	TTCAGTGGCT

FIG. 1G

3751	CCGAGCACAC	CTGGGCATCG	TGTCCCAGGA	GCCCATCCTG	TTTGACTGCA
3801	GCATTGCTGA	GAACATTGCC	TATGGAGACA	ACAGCCGGGT	GGTGTCACAG
3851	GAAGAGATCG	TGAGGGCAGC	AAAGGAGGCC	AACATACATG	CCTTCATCGA
3901	GTCACTGCCT	AATAAATATA	GCACTAAAGT	AGGAGACAAA	GGAACTCAGC
3951	TCTCTGGTGG	CCAGAAACAA	CGCATTGCCA	TAGCTCGTGC	CCTTGTTAGA
4001	CAGCCTCATA	TTTTGCTTTT	GGATGAAGCC	ACGTCAGCTC	TGGATACAGA
4051	AAGTGAAAAG	GTTGTCCAAG	AAGCCCTGGA	CAAAGCCAGA	GAAGGCCGCA
4101	CCTGCATTGT	GATTGCTCAC	CGCCTGTCCA	CCATCCAGAA	TGCAGACTTA
4151	ATAGTGGTGT	TTCAGAATGG	CAGAGTCAAG	GAGCATGGCA	CGCATCAGCA
4201	GCTGCTGGCA	CAGAAAGGCA	TCTATTTTTC	AATGGTCAGT	GTCCAGGCTG
4251	GAACAAAGCG	CCAGTGAACT	CTGACTGTAT	GAGATGTTAA	ATACTTTTTA
4301	ATATTTGTTT	AGATATGACA	TTTATTCAAA	GTTAAAAGCA	AACACTTACA

FIG. 1H

4351	GAATTATGAA	GAGGTATCTG	TTTAACATTT	CCTCAGTCAA	GTTCAGAGTC
4401	TTCAGAGACT	TCGTAATTAA	AGGAACAGAG	TGAGAGACAT	CATCAAGTGG
4451	AGAGAAATCA	TAGTTTAAAC	TGCATTATAA	ATTTTATAAC	AGAATTAAAG
4501	TAGATTTAA	AAGATAAAAT	GTGTAATTTT	GTTTATATTT	TCCCATTTCG
4551	ACTGTAACTG	ACTGCCTTGC	TAAAAGATTA	TAGAAGTAGC	AAAAAGTATT
4601	GAAATGTTTG	CATAAAGTGT	CTATAATAAA	ACTAAACTTT	CATGTGAAAA
4651	AAAAAAAAAA	AAAAAAAAA			

FIG. 2A


Counts
80
70
60
50
40
30
20
10
0
+/- vbl
10^0 10^1 10^2 10^3 10^4
IgG2A-PE,VBL


Counts
vbl
no drug
10^0 10^1 10^2 10^3 10^4
UIC2-PE,VBL


Counts
+/- vbl
10^0 10^1 10^2 10^3 10^4
anti-HLA-DR-PE,VBL


Counts
+/- vbl
10^0 10^1 10^2 10^3 10^4
anti-CD54-PE,VBL

FIG. 2B



FIG. 3A


VINBLASTINE
TAXOL
ACTINOMYCIN D
GRAMICIDIN D
Counts
UIC2
0
10
20
30
40
50
60
10^0
10^1
10^2
10^3
10^4

FIG. 3A CONT.


CYCLOSPORIN A
Counts
60
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4
UIC2


RESERPINE
Counts
60
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4
UIC2


5-FLUOROURACIL
Counts
60
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4
UIC2


METHOTREXATE
Counts
60
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4
UIC2

FIG. 3B


VINBLASTINE
TAXOL
ACTINOMYCIN D
GRAMICIDIN D
Counts
MRK16
60
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4

FIG. 3B CONT.


CYCLOSPORIN A
Counts
60
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4
UIC2


RESERPINE
Counts
60
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4
UIC2


5-FLUOROURACIL
Counts
60
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4
UIC2


METHOTREXATE
Counts
60
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4
UIC2

FIG. 4


VINBLASTINE
TAXOL
VERAPAMIL
COLCHICINE
ETOPOSIDE
PUROMYCIN
Counts
50
40
30
20
10
0
10^0 10^1 10^2 10^3 10^4

FIG. 5A


Counts
60
50
40
30
20
10
0
KK-L
MM
UIC2
10^0
10^1
10^2
10^3
10^4

FIG. 5B


Counts
60
50
40
30
20
10
0
KK-L
MM
MRK16
10^0
10^1
10^2
10^3
10^4

FIG. 5C


60
50
40
30
20
10
0
Counts
MK-H
KM-H
KK-H
UIC2
10^0
10^1
10^2
10^3
10^4

FIG. 5D


60
50
40
30
20
10
0
Counts
KM-H
MK-H
KK-H
MRK16
10^0
10^1
10^2
10^3
10^4

FIG. 6A


Counts
80
70
60
50
40
30
20
10
0
NO DRUG
ETOPOSIDE
TAXOL
VINBLASTINE
KK-L
UIC2
10^0
10^1
10^2
10^3
10^4

FIG. 6B


Counts
80
70
60
50
40
30
20
10
0
NO DRUG
ETOPOSIDE
TAXOL
VINBLASTINE
KK-L
MRK16
10^0
10^1
10^2
10^3
10^4

FIG. 6C


Counts
80
70
60
50
40
30
20
10
0
NO DRUG
ETOPOSIDE
TAXOL
VINBLASTINE
MM
UIC2
10^0
10^1
10^2
10^3
10^4

FIG. 6D


Counts
80
70
60
50
40
30
20
10
0
NO DRUG
ETOPOSIDE
TAXOL
VINBLASTINE
MM
MRK16
10^0
10^1
10^2
10^3
10^4

FIG. 7A


Counts
80
70
60
50
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4
NO DRUG
ETOPOSIDE
TAXOL
VINBLASTINE
KK-H
UIC2

FIG. 7B


Counts
80
70
60
50
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4
NO DRUG
ETOPOSIDE
TAXOL
VINBLASTINE
KK-H
MRK16

FIG. 7C


Counts
80
70
60
50
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4
NO DRUG
ETOPOSIDE
VINBLASTINE
TAXOL
KM-H
UIC2

FIG. 7D


Counts
80
70
60
50
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4
NO DRUG
ETOPOSIDE
TAXOL
VINBLASTINE
KM-H
MRK16

FIG. 7E


Counts
80
70
60
50
40
30
20
10
0
NO DRUG
ETOPOSIDE
VINBLASTINE
TAXOL
MK-H
UIC2
10^0
10^1
10^2
10^3
10^4

FIG. 7F


Counts
80
70
60
50
40
30
20
10
0
NO DRUG
ETOPOSIDE
TAXOL
VINBLASTINE
MK-H
MRK16
10^0
10^1
10^2
10^3
10^4

FIG. 8


A
KK-L
no ATP inhib.+vbl
azide, no vbl
cyanide, no vbl
oligomycin, no vbl
no ATP Inhib., no vbl
Counts
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4
B
KK-H
no ATP inhib.+vbl
azide, no vbl
cyanide, no vbl
oligomycin, no vbl
no ATP Inhib., no vbl
Counts
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4

FIG. 8 CONT.

C


KM-H
no ATP inhib.+vbl
azide, no vbl
cyanide, no vbl
oligomycin, no vbl
no ATP Inhib., no vbl
Counts
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4

D


MK-H
no ATP inhib.+vbl
azide, no vbl
cyanide, no vbl
oligomycin, no vbl
no ATP Inhib., no vbl
Counts
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4

FIG. 8 CONT.


E
MM
no ATP inhib., no vbl
no ATP inhib.+vbl
azide, no vbl
cyanide, no vbl
oligomycin, no vbl
Counts
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4

FIG. 9A


unts
azide, 50 µl
(91%)
Counts
cyanide, 10 µl
(96%)
unts
azide, 10 µl
(91%)
Counts
cyanide, 2 µl
(86%)
0
10
20
30
40
50
60
70
80
10^0
10^1
10^2
10^3
10^4

FIG. 9B


azide, 2 µl
(83%)
cyanide, 0.4 µl
(83%)
azide, 0.4 µl
(63%)
cyanide, 0.4 µl
(25%)
Counts
Counts
80
70
60
50
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4

FIG. 9C


Counts
80
70
60
50
40
30
20
10
0
cyanide, 0.02 µl
(6%)
10^0
10^1
10^2
10^3
10^4

FIG. 10A


azide, 16 µl
(95%)
Counts
UIC2
cyanide, 8 µl
(95%)
Counts
UIC2
azide, 8 µl
(84%)
Counts
UIC2
cyanide, 4 µl
(94%)
Counts
UIC2

FIG. 10A CONT.


Counts
60
50
40
30
20
10
0
azide, 4 µl
(76%)
10^0
10^1
10^2
10^3
10^4
UIC2


Counts
60
50
40
30
20
10
0
cyanide, 2 µl
(74%)
10^0
10^1
10^2
10^3
10^4
UIC2

FIG. 10B


azide, 16 µl
cyanide, 8 µl
azide, 8 µl
cyanide, 4 µl
Counts
MRK16
0
10
20
30
40
50
60
10^0
10^1
10^2
10^3
10^4

FIG. 10B CONT.


azide, 4 µl
Counts
60
50
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4
MRK16


cyanide, 2 µl
Counts
60
50
40
30
20
10
0
10^0
10^1
10^2
10^3
10^4
MRK16

FIG. 11


60
50
40
30
20
10
0
Counts
UIC2 PE, NO DRUG
BONE MARROW
UIC2 PE, VINBLASTINE
10^0
10^1
10^2
10^3
10^4
UIC2 PE

FIG. 12


CORD BLOOD
NO DRUG
UIC2 PE
CD34 APC
10^0
10^1
10^2
10^3
10^4


CORD BLOOD
VINBLASTINE
UIC2 PE
CD34 APC
10^0
10^1
10^2
10^3
10^4